Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Cash & Current Investments (2019 - 2025)

Pulmonx (LUNG) has disclosed Cash & Current Investments for 7 consecutive years, with $8.8 million as the latest value for Q2 2025.

  • On a quarterly basis, Cash & Current Investments fell 92.35% to $8.8 million in Q2 2025 year-over-year; TTM through Dec 2024 was $101.5 million, a 13.34% decrease, with the full-year FY2024 number at $101.5 million, down 13.34% from a year prior.
  • Cash & Current Investments was $8.8 million for Q2 2025 at Pulmonx, down from $14.1 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $219.1 million in Q1 2021 to a low of $8.8 million in Q2 2025.
  • A 5-year average of $132.1 million and a median of $138.1 million in 2022 define the central range for Cash & Current Investments.
  • Peak YoY movement for Cash & Current Investments: skyrocketed 1248.85% in 2021, then tumbled 92.35% in 2025.
  • Pulmonx's Cash & Current Investments stood at $180.0 million in 2021, then fell by 21.61% to $141.1 million in 2022, then dropped by 17.03% to $117.1 million in 2023, then dropped by 13.34% to $101.5 million in 2024, then crashed by 91.37% to $8.8 million in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Cash & Current Investments are $8.8 million (Q2 2025), $14.1 million (Q1 2025), and $101.5 million (Q4 2024).